https://mindmedicinelaw.com/briefing/acsi-s-dea-application-impact-on-psychedelic-research-20260630-17798The Psychedelic Journalen2026-06-30T15:04:55.275906+00:00ACSI's DEA Application: Impact on Psychedelic ResearchACSI, DEA application, controlled substances import, psychedelic research, clinical trials, supply chain, regulatory compliance, psilocybin, MDMA, public healthhttps://mindmedicinelaw.com/briefing/sacramento-s-psychedelic-use-for-mental-health-trends-and-implications-20260630-17886The Psychedelic Journalen2026-06-30T15:04:36.252142+00:00Sacramento's Psychedelic Use for Mental Health: Trends and Implicationssacramento psychedelics, mental health treatment, self-medication, psychedelic research, regulatory frameworks, psilocybin and MDMA, clinical trials, public health implicationshttps://mindmedicinelaw.com/briefing/definium-s-phase-3-lsd-trial-success-and-industry-impact-20260630-17885The Psychedelic Journalen2026-06-30T15:04:22.430628+00:00Definium's Phase 3 LSD Trial Success and Industry ImpactDefinium, LSD trial, psychedelic medicine, clinical trials, regulatory implications, market dynamics, mental health, FDA, Schedule I substance, therapeutic applicationshttps://mindmedicinelaw.com/briefing/fda-s-rems-path-for-comp360-impact-on-psychedelic-industry-20260629-17795The Psychedelic Journalen2026-06-29T22:03:54.405285+00:00FDA's REMS Path for COMP360: Impact on Psychedelic IndustryFDA, REMS, COMP360, psychedelic industry, regulatory framework, clinical trials, drug safetyhttps://mindmedicinelaw.com/briefing/trump-s-executive-order-accelerates-psychedelic-therapies-20260629-17633The Psychedelic Journalen2026-06-29T15:05:06.663131+00:00Trump's Executive Order Accelerates Psychedelic Therapiespsychedelic therapies, executive order, Trump, FDA, clinical trials, market access, investor confidence, regulatory risks, mental health, Compass Pathwayshttps://mindmedicinelaw.com/briefing/new-tools-enhance-psychedelic-trial-assessment-and-credibility-20260628-17553The Psychedelic Journalen2026-06-29T22:04:42.147612+00:00New Tools Enhance Psychedelic Trial Assessment and Credibilitypsychedelic clinical trials, regulatory alignment, transparency, reproducibility, trial assessment tools, market acceptance, FDA, EMA, protocol evaluation, psychedelic researchhttps://mindmedicinelaw.com/briefing/kolmogorov-theory-s-role-in-personalized-brain-stimulation-20260628-17551The Psychedelic Journalen2026-06-29T22:04:32.802125+00:00Kolmogorov Theory's Role in Personalized Brain Stimulationkolmogorov theory, consciousness, brain stimulation, neuropsychiatric disorders, computational neuroscience, clinical trials, personalized medicine, neurotwin technology, transcranial electrical stimulation, psychedelic stateshttps://mindmedicinelaw.com/briefing/psychedelic-integration-governance-scoping-review-insights-20260628-17554The Psychedelic Journalen2026-06-29T22:04:23.003390+00:00Psychedelic Integration Governance: Scoping Review Insightspsychedelic integration, governance, ethics of integration, marginalized communities, clinical trials, cultural settings, standardized practices, policy development, risk management, knowledge systemshttps://mindmedicinelaw.com/briefing/new-tools-enhance-psychedelic-trial-assessment-and-transparency-20260628-17556The Psychedelic Journalen2026-06-29T22:04:13.631588+00:00New Tools Enhance Psychedelic Trial Assessment and Transparencypsychedelic clinical trials, transparency in research, regulatory alignment, qualitative assessment dataset, quantitative assessment dataset, FDA approval process, EMA regulatory standards, reproducibility in sciencehttps://mindmedicinelaw.com/briefing/microdosing-psychedelics-mood-and-cognition-insights-20260628-17616The Psychedelic Journalen2026-06-29T15:06:30.935489+00:00Microdosing Psychedelics: Mood and Cognition Insightspsychedelic microdosing, mood enhancement, cognitive function, serotonin receptors, neuroplasticity, clinical trials, mental health treatment, regulatory frameworks, long-term effects, self-medication riskshttps://mindmedicinelaw.com/briefing/quantifying-psychedelic-experiences-new-frameworks-and-challenges-20260628-17552The Psychedelic Journalen2026-06-29T15:06:12.133391+00:00Quantifying Psychedelic Experiences: New Frameworks and Challengespsychedelic research, computational framework, large language models, subjective experiences, ethical concerns, mystical experiences, phenomenology, demographic bias, mystical-score saturation, neurosciencehttps://mindmedicinelaw.com/briefing/kolmogorov-theory-framework-in-psychedelic-research-20260628-17555The Psychedelic Journalen2026-06-29T15:06:00.811717+00:00Kolmogorov-Theory Framework in Psychedelic ResearchKolmogorov-Theory framework, psychedelic research, subjective experiences, large language models, mental health, demographic bias, epistemological challenges, computational phenomenologyhttps://mindmedicinelaw.com/briefing/kolmogorov-theory-s-role-in-neuropsychiatry-and-psychedelics-20260628-17557The Psychedelic Journalen2026-06-29T15:05:36.833529+00:00Kolmogorov Theory's Role in Neuropsychiatry and Psychedelicskolmogorov theory, neuropsychiatry, computational neuroscience, personalized brain stimulation, psychedelic research, neurotwin technology, clinical trials, consciousness, emotional states, brain stimulation therapieshttps://mindmedicinelaw.com/briefing/microdosing-psychedelics-cognitive-impairment-and-mood-myths-20260628-17558The Psychedelic Journalen2026-06-29T15:05:21.175233+00:00Microdosing Psychedelics: Cognitive Impairment and Mood Mythspsychedelic microdosing, cognitive impairment, mood benefits, LSD, psilocybin, expectancy bias, clinical trials, cardiovascular risks, 5-HT 2 B receptor, placebo-controlledhttps://mindmedicinelaw.com/briefing/psilocybin-s-role-in-fear-memory-and-neuroplasticity-implications-20260628-17469The Psychedelic Journalen2026-06-28T22:04:05.155593+00:00Psilocybin's Role in Fear Memory and Neuroplasticity: Implicationspsilocybin, fear memory, neuroplasticity, PTSD treatment, psychedelic research, mental health, serotonin receptors, clinical trials, policy implications, brain regionshttps://mindmedicinelaw.com/briefing/psychosocial-protocols-in-psychedelic-therapy-a-scoping-review-20260626-17786The Psychedelic Journalen2026-06-30T15:05:08.927937+00:00Psychosocial Protocols in Psychedelic Therapy: A Scoping Reviewpsychedelic therapy, psychosocial protocols, clinical trials, safety and efficacy, therapeutic guidelines, integration phase, standardization, regulatory approval, therapeutic outcomes, psychedelic experienceshttps://mindmedicinelaw.com/briefing/u-s-psychedelic-use-and-microdosing-2025-survey-insights-20260626-17785The Psychedelic Journalen2026-06-29T22:04:04.395494+00:00U.S. Psychedelic Use and Microdosing: 2025 Survey Insightspsychedelic use, microdosing, 2025 survey, U.S. trends, public health, research priorities, regulatory frameworks, mental health, safety protocols, long-term effectshttps://mindmedicinelaw.com/briefing/rethinking-psychiatric-medication-in-bpd-treatment-20260622-17581The Psychedelic Journalen2026-06-30T15:05:34.373514+00:00Rethinking Psychiatric Medication in BPD Treatmentborderline personality disorder, psychiatric medication, biomedical model, mental health treatment, psychopharmacology, patient narratives, symbolic role of medication, relational dynamics, mental health policy, treatment strategieshttps://mindmedicinelaw.com/briefing/opioid-receptor-activation-by-pcp-and-ketamine-structural-insights-20260622-17624The Psychedelic Journalen2026-06-30T15:05:21.911784+00:00Opioid Receptor Activation by PCP and Ketamine: Structural Insightsopioid receptor activation, PCP, ketamine, structural insights, therapeutic potential, safety profiles, neuroscience, clinical trials, public health, translational research